Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

CME Oversight: Are Sponsor Logos Promotions Or Transparency Enhancements?

  • News

Executive Summary

The Accreditation Council for Continuing Medical Education will continue to study whether using logos to identify corporate sponsors of CME furthers transparency or promotes the sponsor.

You may also be interested in...



Demographics Of Commenters On ACCME Proposed Policy Changes

Physician Payments Sunshine Rule From CMS Expected By Year's End

Pharmaceutical companies will have a little more than a year to put together data to comply with CMS regulations for reporting payments made to physicians if the agency meets its current timeline for issuing the rules.

CME Programs Weather Drop In Industry Funding

Accreditation Council for Continuing Medical Education reports that industry funding of CME programs fell 29 percent from 2007 to 2009.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS053699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By